Analyst Price Target is $42.00
▲ +1,029.03% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $42.00, with a high forecast of $70.00 and a low forecast of $14.00. The average price target represents a 1,029.03% upside from the last price of $3.72.
Current Consensus is
The current consensus among 3 investment analysts is to moderate buy stock in Evaxion Biotech A/S. This Moderate Buy consensus rating has held steady for over two years.
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.